Opus Genetics, Inc. (NASDAQ:IRD – Get Free Report) CEO George Magrath acquired 90,294 shares of the firm’s stock in a transaction that occurred on Friday, November 15th. The stock was purchased at an average price of $1.01 per share, with a total value of $91,196.94. Following the completion of the acquisition, the chief executive officer now owns 483,244 shares in the company, valued at $488,076.44. The trade was a 22.98 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.
George Magrath also recently made the following trade(s):
- On Monday, November 18th, George Magrath bought 9,706 shares of Opus Genetics stock. The stock was acquired at an average cost of $1.02 per share, with a total value of $9,900.12.
Opus Genetics Stock Down 3.0 %
Shares of NASDAQ IRD traded down $0.03 during trading on Tuesday, reaching $0.88. 243,421 shares of the company traded hands, compared to its average volume of 173,666. Opus Genetics, Inc. has a 52-week low of $0.85 and a 52-week high of $3.40.
Analyst Upgrades and Downgrades
Separately, HC Wainwright initiated coverage on Opus Genetics in a report on Wednesday, November 13th. They set a “buy” rating and a $8.00 price target on the stock.
Read Our Latest Stock Report on IRD
Opus Genetics Company Profile
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.
Read More
- Five stocks we like better than Opus Genetics
- What is a Secondary Public Offering? What Investors Need to Know
- Super Micro Computer Soars 28%: Is It Really Out of the Woods?
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Traders Are Flocking Back to Oil: What’s Fueling the Optimism
- What is a Bond Market Holiday? How to Invest and Trade
- 3 Hot Stock Trends to Ride Into 2025
Receive News & Ratings for Opus Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opus Genetics and related companies with MarketBeat.com's FREE daily email newsletter.